Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer.
Location: United States, Massachusetts, Newton
Employees: 201-500
Total raised: $97.2M
Founded date: 2008
Investors 5
| Date | Name | Website |
| - | PFM Health... | pfmhealths... |
| - | Foresite C... | foresiteca... |
| - | Avoro Capi... | avorocapit... |
| - | Delphi Ven... | delphivent... |
| - | New Leaf V... | nlvpartner... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 01.08.2013 | - | $19M | - |
| 20.05.2013 | Series B | $48.2M | - |
| 02.11.2011 | - | $10M | - |
| 03.11.2010 | Series A | $20M | - |
Mentions in press and media 27
| Date | Title | Description | Source |
| 18.04.2023 | Karyopharm Announces Presentation of Updated Phase 1 Selinex... | – At Week 24, 60mg of Selinexor in Combination with Ruxolitinib Achieved: 92% SVR35 and 78% TSS50 in... | einpresswi... |
| 21.02.2023 | Karyopharm and Menarini Group Receive Full Marketing Authori... | – Based on Results from Phase 3 BOSTON Study, Marketing Authorization Expands Multiple Myeloma Indic... | en.prnasia... |
| 01.11.2022 | Karyopharm and Menarini Group Announce Orphan Medicinal Prod... | NEWTON, Mass. and FLORENCE, Italy, Nov. 1, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ... | en.prnasia... |
| 21.07.2022 | Karyopharm and Menarini Group Receive Full Marketing Authori... | – Based on Results from Phase 3 BOSTON Study, Marketing Authorisation Expands Multiple Myeloma Indic... | en.prnasia... |
| 21.05.2022 | Karyopharm and Menarini Group Receive Positive CHMP Opinion ... | -- European Commission Decision Anticipated within Approximately 60 Days -- NEWTON, Mass. and FLORE... | en.prnasia... |
| 22.12.2021 | Karyopharm and Menarini Group Enter into Exclusive License A... | - Menarini Group Obtains Exclusive Rights to Commercialize NEXPOVIO for the Treatment of Hematologic... | en.prnasia... |
| 17.12.2021 | Karyopharm's Partner Antengene Receives Approval in China fo... | NEWTON, Mass., Dec. 17, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commerci... | marketscre... |
| 03.11.2021 | Karyopharm Reports Strong Third Quarter 2021 Financial Resul... | NEWTON, Mass., Nov. 3, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial... | marketscre... |
| 21.10.2021 | Karyopharm Therapeutics : Announces Dosing of First Patient ... | NEWTON, Mass., Oct. 21, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercia... | marketscre... |
| 28.07.2021 | Karyopharm Therapeutics : Announces Dosing of First Patients... | NEWTON, Mass., July 28, 2021 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commerci... | marketscre... |
Show more